Trials / Completed
CompletedNCT02294851
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo controlled, single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
Detailed description
This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986168 | |
| DRUG | BMS-986168 Placebo |
Timeline
- Start date
- 2014-12-31
- Primary completion
- 2016-04-30
- Completion
- 2016-04-30
- First posted
- 2014-11-19
- Last updated
- 2017-11-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02294851. Inclusion in this directory is not an endorsement.